Servizio di Immunematologia e Medicina Trasfusionale e Centro di Immunologia dei Trapianti, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Clin Chim Acta. 2011 Oct 9;412(21-22):1995-8. doi: 10.1016/j.cca.2011.07.003. Epub 2011 Jul 8.
Increasing the safety in Immunogenetics Labs, in the era of antiretroviral pharmacogenomics, represents an imperative goal. To this purpose, we tested saliva and buccal cells as biological sources of DNA, alternative to peripheral blood, for HLA-B*57:01 genomic typing of HIV positive patients eligible to treatment with abacavir.
Blood, saliva and buccal cells of 20 voluntary donors and 20 HIV positive patients were collected. DNA was extracted with a manual commercial kit and an automated platform. Quality and quantity of DNA was evaluated with different procedures. The suitability and reliability of DNAs for HLA-B*57:01 genotyping was checked at low and high resolution level, using PCR-SSP (sequence specific primers PCR), revPCR-SSO (reverse sequence specific oligonucleotides PCR), bead array and SBT (sequence based typing) techniques.
DNA concentrations were qualitatively very good and quantitatively comparable in all the specimens tested with an inferior yield for cotton swabs. Comparing the results of HLA typing with different methodologies, the 100% of reproducibility was achieved.
The viral load of buccal epithelial cells or saliva is extremely low. Here we demonstrated that the DNA from these alternative sources is appropriate for HLA-B*57:01 typing. We strongly recommend the use of this procedure to increase the safety in the lab when dealing with infectious samples.
在抗逆转录病毒药物基因组学时代,提高免疫遗传学实验室的安全性是当务之急。为此,我们测试了唾液和颊拭子作为替代外周血的 DNA 生物来源,用于对适合使用阿巴卡韦治疗的 HIV 阳性患者进行 HLA-B*57:01 基因组分型。
采集 20 名志愿供者和 20 名 HIV 阳性患者的血液、唾液和颊拭子。使用手动商业试剂盒和自动化平台提取 DNA。使用不同的程序评估 DNA 的质量和数量。使用 PCR-SSP(序列特异性引物 PCR)、revPCR-SSO(反向序列特异性寡核苷酸 PCR)、珠阵列和 SBT(基于序列的分型)技术在低和高分辨率水平检查 DNA 用于 HLA-B*57:01 基因分型的适用性和可靠性。
在所测试的所有标本中,DNA 浓度的定性非常好,定量也相当,棉签的产量较低。比较不同方法学的 HLA 分型结果,达到了 100%的重现性。
颊上皮细胞或唾液中的病毒载量极低。在这里,我们证明了这些替代来源的 DNA 适合 HLA-B*57:01 分型。我们强烈建议在处理感染性样本时使用此程序来提高实验室的安全性。